Patent ID: 9205082
Filing Date: 2015-12-08
Classification: A61K,A61P,Y10S

Abstract:
1. A sustained release oral dosage form, comprising: an orally therapeutically effective dose of an opioid agonist selected from oxycodone and pharmaceutically acceptable salts thereof which is present in the dosage form in an amount that is equianalgesic to about 8 mg to about 50 mg hydrocodone or a pharmaceutically acceptable salt thereof, about 2 mg to about 64 mg hydromorphone hydrochloride, about 2.5 mg to about 800 mg morphine or a pharmaceutically acceptable salt thereof, or about 25 mg to about 800 mg tramadol or a pharmaceutically acceptable salt thereof; an opioid antagonist selected from naloxone and pharmaceutically acceptable salts thereof; and a sustained release carrier that contains the opioid agonist and the opioid antagonist; said dosage form having a ratio of opioid antagonist to opioid agonist that provides a combination product which is analgesically effective when the combination product is administered orally, but which such that said dosage form is administrable on a twice-a-day or on a once-a-day basis.